Abstract 30P
Background
Metastatic breast cancer (mBC) remains a leading cause of cancer-related deaths among women globally. Despite advances, many treatments fail to improve patient outcomes, emphasizing the need for innovative approaches and reliable biomarkers to better predict treatment response. Recent studies show that neutrophils play a critical role in cancer, with low density neutrophils (LDN) acting as key modulators in the tumor microenvironment. LDN are linked to tumor growth and metastasis, contributing to an immunosuppressive environment that supports cancer progression. Here, we investigated the clinical significance of LDN in breast cancer (BC) by assessing their association with disease progression and patient outcomes.
Methods
We analysed blood samples from 146 BC patients (78 non-metastatic, 68 metastatic), isolating both LDN and high-density neutrophils (HDN, conventional neutrophils) by density gradient centrifugation. Flow cytometry was used to quantify and characterize the populations.
Results
Our results show significant LDN accumulation in BC patients’ blood, particularly those with metastatic disease. Importantly, elevated LDN levels were linked to reduced life expectancy in these patients, regardless of metastatic site (bone, lung or brain). Moreover, the increase in LDN levels was often accompanied by a decrease in HDN, leading to an imbalance favoring protumor neutrophils. Additionally, preliminary data from a small cohort of triple-negative BC patients (n=7, ongoing recruitment) undergoing immunotherapy suggest that higher pre-treatment LDN levels may predict poorer treatment response. This early finding points to LDN’ potential as predictive biomarkers for immunotherapy efficacy in BC.
Conclusions
Our study highlights the prognostic value of LDN in BC, with elevated levels linked to advanced disease and worse clinical outcomes. These findings suggest that LDN could serve as valuable biomarkers for monitoring disease progression and predict treatment response, identifying patients at greater risk. Ultimately, incorporating LDN assessment into clinical practice may guide treatment strategies, offering a more personalized approach to BC management and potentially improving therapeutic outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract